Posted by Michael Wonder on 16 Aug 2022
Lynparza in combination with abiraterone granted priority review in the US for patients with metastatic castration-resistant prostate cancer
16 August 2022 - First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent irrespective of homologous recombination repair gene mutations,
AstraZeneca’s supplemental new drug application for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted priority review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer.
